8-K: Finch Therapeutics Wins Patent Infringement Case Against Ferring Pharmaceuticals, Awarded $25.815 Million

Finch Therapeutics and the University of Minnesota won a patent infringement case against Ferring Pharmaceuticals, securing a $25 million upfront payment and $0.815 million in running royalties.

Summary

• Finch Therapeutics and the University of Minnesota (UMN) have been in litigation with Rebiotix Inc. and Ferring Pharmaceuticals Inc. regarding certain patents.
• The trial took place in the U.S. District Court for the District of Delaware, starting on August 5, 2024.
• The case involved five asserted patent claims from three patents.
• Finch Therapeutics asserted two claims each from United States Patents 10,675,309 and 11,541,080.
• UMN asserted one claim from United States Patent 10,251,914.
• On August 9, 2024, the jury found that Ferring had infringed on the asserted claims and that the infringement was willful.
• The jury also found that one claim each from the 309 and 080 patents was invalid, but the remaining claims were not invalid.
• The jury awarded Finch Therapeutics and UMN a $25.0 million upfront payment and $0.815 million in running royalties.
• These royalties are for commercial sales of Rebyota, a microbiome-based therapy marketed by Ferring, from its launch to the trial date.
• Finch Therapeutics anticipates that Ferring will file post-trial motions and appeal any judgment based on the jury's verdict.

Sentiment

Score: 8

Explanation: The document reflects a positive outcome for Finch Therapeutics with a significant financial award, although the potential for appeals introduces some uncertainty.

Positives

• The jury found that Ferring infringed on Finch's and UMN's patents.
• The infringement was deemed willful by the jury.
• Finch and UMN will receive a significant upfront payment of $25 million.
• They will also receive $0.815 million in running royalties.
• The jury upheld the validity of three of the five asserted patent claims.

Negatives

• The jury found two of the five asserted patent claims to be invalid.
• Ferring is expected to file post-trial motions and appeal the judgment.

Risks

• Ferring is expected to file post-trial motions, which could potentially overturn or modify the jury's verdict.
• The outcome of any appeals process is uncertain and could impact the final financial award.
• The running royalties are only for sales up to the trial date, future royalties are not guaranteed.

Future Outlook

Finch Therapeutics expects Ferring to file post-trial motions and pursue an appeal of any judgment entered on the jury's verdict.

Management Comments

• The company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
• Matthew P. Blischak, Chief Executive Officer, signed the report.

Industry Context

This legal victory for Finch Therapeutics highlights the importance of intellectual property protection in the competitive microbiome therapeutics industry. It also underscores the potential financial impact of patent litigation on pharmaceutical companies.

Comparison to Industry Standards

• Patent litigation is common in the pharmaceutical industry, with companies like AbbVie, Amgen, and Regeneron frequently involved in similar disputes.
• The $25.815 million award is significant for a company of Finch's size, but it is not unusual for patent infringement cases to result in much larger awards.
• For example, in 2023, a jury awarded $1.2 billion to a company in a patent dispute over cancer treatment technology.
• The running royalty component is also a common feature of patent infringement settlements, with rates varying depending on the specific technology and market.

Legal Proceedings

• Finch Therapeutics and UMN were involved in a patent infringement lawsuit against Ferring Pharmaceuticals.
• The jury found Ferring had infringed on the asserted claims.

Stakeholder Impact

• Shareholders of Finch Therapeutics will likely view this as a positive development due to the financial award.
• The outcome could also impact the company's future strategic decisions and financial stability.
• The legal victory could enhance the company's reputation and credibility in the industry.

Next Steps

• Finch Therapeutics anticipates Ferring will file post-trial motions.
• Finch Therapeutics expects Ferring to pursue an appeal of any judgment entered on the jury's verdict.

Key Dates

Keywords

patent infringement, Finch Therapeutics, Ferring Pharmaceuticals, Rebyota, litigation, royalties, intellectual property, microbiome therapy